MK0752 in Treating Young Patients With Recurrent or Refractory CNS Cancer
Status:
Terminated
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
RATIONALE: MK0752 may stop the growth of tumor cells by blocking some of the enzymes needed
for cell growth.
PURPOSE: This phase I trial is studying the side effects and best dose of MK0752 in treating
young patients with recurrent or refractory CNS cancer.